Ourofino Saúde Animal (Ourofino Animal Health) posted a substantial growth in its third-quarter results, with a 315.5% increase in adjusted net profit, reaching R$ 42.4 million compared to the same period in 2023. The company also reported a 7.4% rise in net revenue, totaling R$ 283.3 million, driven by strong performance across its core business segments and growing demand for its products.
The adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 30.9%, amounting to R$ 74.7 million, while the adjusted EBITDA margin improved by 4.8 percentage points, reaching 26.4%.
The company also saw a 22.3% reduction in net debt, reflecting solid cash generation during the period and the settlement of R$ 35 million in working capital debt. Its financial leverage ratio stood at 0.6x adjusted EBITDA, compared to 0.5x at the end of Q3 2023.
“We maintain the strength of our financial health, evidenced by another period of robust cash generation and low debt levels with a long-term profile. Our costs are aligned with the business needs, enabling us to sustain a strategic investment agenda in research, development, and innovation while maintaining healthy liquidity levels,” Ourofino stated in its earnings release.
In the production animal segment, the company reported a net revenue of R$ 211.5 million in the quarter ending September, an increase of 4.3% from the same period last year. The companion animal unit saw a 25.9% increase in revenue, totaling R$ 41.2 million.
International operations also performed well, with a 8.2% increase in net revenues, reaching R$ 30.5 million.
